Company profile: Pharnext
1.1 - Company Overview
Company description
- Provider of clinical-stage biopharmaceutical therapeutics for severe neurodegenerative diseases, developing PXT3003 for Charcot-Marie-Tooth disease type 1A using its Pleotherapy approach (Phase III), and PXT864, a fixed-dose combination of baclofen and acamprosate progressing to Phase 2a in ALS; also sponsors CMT&Me, an app-based international study of CMT patient lifestyles.
Products and services
- CMT&Me Study: An app-based international study sponsored by Pharnext that investigates the impact of Charcot-Marie-Tooth disease on patients’ lifestyles across participating countries
- PXT3003: A Pleotherapy-based drug candidate for Charcot-Marie-Tooth disease type 1A, currently advancing through Phase III clinical trials to address this severe hereditary neuropathy
- PXT864: A fixed-dose combination therapy of baclofen and acamprosate initially evaluated in Alzheimer’s, now prepared for Phase 2a clinical trials targeting Amyotrophic Lateral Sclerosis
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Pharnext
Cognition Therapeutics
HQ: United States
Website
- Description: Provider of neurodegenerative disease therapeutics, developing CT1812, an oral sigma-2 receptor-targeting therapy aimed at slowing progression of Alzheimer’s disease, dementia with Lewy bodies, and dry age-related macular degeneration. The company conducts clinical trials on CT1812's safety and efficacy and researches sigma-2 receptor modulators to restore neuronal responses and prevent/displace toxic protein buildup in neurons.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cognition Therapeutics company profile →
Proximagen
HQ: United Kingdom
Website
- Description: Provider of neuroscience research and drug development targeting neurodegenerative disorders, including Parkinson's disease and Alzheimer's disease; publicly traded.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Proximagen company profile →
Xanodyne
HQ: United States
Website
- Description: Provider of integrated specialty pharmaceutical products, developing and commercializing offerings in women's healthcare and pain management in the United States.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Xanodyne company profile →
Spiegelberg
HQ: Germany
Website
- Description: Provider of catheters and probes for neurosurgical use in the brain, as well as antimicrobial products to prevent hospital-acquired infections; began operation in 1986 and is headquartered in Hamburg, Germany.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Spiegelberg company profile →
Cognito Therapeutics
HQ: United States
Website
- Description: Provider of non-invasive gamma wave therapy that evokes brain gamma activity via visual and auditory stimulation to slow cognitive and functional decline in Alzheimer’s; personalized intensity guided by EEG. Runs the HOPE pivotal study and Phase 2 OVERTURE showing preserved cognition, daily function, and brain volume. Holds FDA Breakthrough Device Designation; developing disease-modifying treatments for CNS illnesses.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cognito Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Pharnext
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Pharnext
2.2 - Growth funds investing in similar companies to Pharnext
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Pharnext
4.2 - Public trading comparable groups for Pharnext
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →